Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | GALT | Stock Option (right to buy) | Award | $0 | +91K | $0.00 | 91K | Jan 24, 2024 | Common Stock | 91K | $1.72 | Direct | F1, F2 | |
transaction | GALT | Restricted Stock Unit | Award | $0 | +56K | $0.00 | 56K | Jan 24, 2024 | Common Stock | 56K | Direct | F3, F4 |
Id | Content |
---|---|
F1 | The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. |
F2 | The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025. |
F3 | The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. |
F4 | Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested. |